Research programme: oral peptides - MonoSol Rx

Drug Profile

Research programme: oral peptides - MonoSol Rx

Alternative Names: Exenatide buccal delivery - MonoSol Rx; Octreotide buccal delivery - MonoSol Rx

Latest Information Update: 28 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MonoSol Rx
  • Class Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 01 Apr 2015 Preclinical trials in Undefined indication in USA (Buccal)
  • 20 Dec 2012 MonoSol Rx has patent protection for PharmFilm® drug delivery technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top